20th week of 2015 patent applcation highlights part 40 |
Patent application number | Title | Published |
20150132226 | TREATMENT OF CANCER - This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of cancer. Leucine-rich alpha-2-glycoprotein (Lrg1) has been demonstrated to be expressed in a range of cancer cells. Antagonists of Lrg1 can be used to prevent and/or treat cancer by an effect on neoplastic cells. | 2015-05-14 |
20150132227 | NOVEL ECHOGENIC CONTRAST AGENTS - Disclosed are compositions and methods for related to echogenic contrast agents. Also disclosed are methods and compositions for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for producing a medical image of a tissue. Also disclosed are methods of monitoring the progression of eosinophilic esophagitis in a subject before, during, and after treatment. | 2015-05-14 |
20150132228 | COMPOSITIONS AND METHODS TO EVALUATE HEPATOBILIARY/GASTROINTESTINAL HEALTH, ENTEROHEPATIC CIRCULATION, AND DRUG INTERACTIONS - The present invention relates to the synthesis and use of a novel trifluorinated bile acid analogue, that being, CA-sar-TFMA which is useful as an imaging probe, diagnostic agent or contrast agent and is resistant to bacterial deconjugation, wherein the trifluorinated bile acid analogue can be used as a | 2015-05-14 |
20150132229 | BIS AZAINOSITOL HEAVY METAL COMPLEXES FOR X-RAY IMAGING - The present invention describes a new class of trinuclear heavy metal complexes comprising two hexadentate azainositol tricarboxylic acid ligands, a method for their preparation and their use as X-ray contrast agents. | 2015-05-14 |
20150132230 | PROTEASE ASSAY - The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis. | 2015-05-14 |
20150132231 | SURFACE FUNCTIONALIZATION OF SUPERPARAMAGNETIC NANOPARTICLES FOR BIOLOGICAL ENCAPSIDATION - Method and compositions are provided that relate to superparamagnetic nanoparticles, including IONP with small diameter and high transverse relaxivity, that are stable in an aqueous environment. The nanoparticle surface coating is functionalized, while minimizing its thickness, to facilitate packaging within biological constructs. | 2015-05-14 |
20150132232 | Method and Composition for Oral Health Care Treatment - A method for oral health treatment of a subject using a composition having an anti-oxidant enzyme, an anti-inflammatory agent, and a pharmaceutically acceptable buffer. In certain embodiments, the compositions are administered to the subjection in conjunction with teeth whitening, oral surgery, oral pathology treatment, endodontic therapy, periodontal therapy, dental restoration, preventative tooth cleaning, or subsequent to a pro-oxidant. | 2015-05-14 |
20150132233 | COMPOSITIONS CONTAINING THEOBROMINE AND THEIR USE IN TREATING TOOTH HYPERSENSITIVITY - Compositions and methods for reducing oral sensitivity, increasing the systemic health of a mammal, occluding a dentinal tubule within a mammalian tooth, and/or depositing a precipitate on the surface of a mammalian tooth are provided, said compositions comprising theobromine (3,7-dimethylxanthine, the principal alkaloid in | 2015-05-14 |
20150132234 | FOUNTAIN OF YOUTH - Steeped Herbal Anti-Bacterial Body Water For Consumption And Topical Use - The Thyme Lavender Oregano Mint Neem Solution For Acne, Eyelash And Pore Cleansing, Wrinkles, Body Odors, Breath Freshening, Vaginal Douching, Toenail Fungus, Blephritis, Comedones, Wound Care, And More... - This innovation is a unique, natural, CONSUMABLE and topical treatment for many of my body's ailments that has helped me in ways other products never did. The anti-bacterial herbs appear to fight the root cause of the many ailments listed, instead of just masking them. | 2015-05-14 |
20150132235 | COSMETIC COMPOSITION COMPRISING A MUCONOPEPTIDE - A cosmetic composition including as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide It further concerns a composition wherein the mu-conotoxin peptide is Argninine, lysine polypeptide, CAS Number: 937286-43-6, Molecular formula C | 2015-05-14 |
20150132236 | COMPOSITIONS CONTAINING LOW LEVELS OF COLORANT TO ENHANCE SKIN APPEARANCE - A composition for providing enhanced skin appearance, particularly in terms of providing the appearance of reduced dryness and flakiness for an extended period of time, is disclosed. The compositions include low levels of skin coloring agents, including self-tanning compounds, such as DHA and/or erythrulose, in a topical cosmetic base. The levels of self-tanning compounds utilized are lower than those typically found in self-tanning compositions. A method for enhancing skin appearance utilizing those compositions is also disclosed. | 2015-05-14 |
20150132237 | COMPOSITION USING CROSS-LINKED HYALURONIC ACID FOR TOPICAL COSMETIC AND THERAPEUTIC APPLICATIONS - Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin. | 2015-05-14 |
20150132238 | COMPOSITION USING CROSS-LINKED HYALURONIC ACID FOR TOPICAL COSMETIC AND THERAPEUTIC APPLICATIONS - Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin. | 2015-05-14 |
20150132239 | MATERIAL FORMED FROM DENDRITIC MOLECULES CONTAINING ASSOCIATIVE GROUPS - The present invention relates to a material comprising dendritic molecules each constituted of fragments that are at least bifunctional and of fragments that are of least trifunctional joined together by ester or thioester bridges, alone or in combination with amide or urea bridges, said bridges being formed from two functions carried by different fragments, said molecules containing, on the fragments located at the ends of the dendritic branches, associative end groups capable of forming associations with one another by hydrogen bonds and joined covalently to the functions that are not involved in said bridges. It also relates to the method of production thereof, as well as to its uses and to compositions, notably cosmetic, containing this material. | 2015-05-14 |
20150132240 | Topical Composition And Method For Skin Treatment - A topical composition and method for skin treatment including a wound healing agent in combination with a wound concealing agent, is disclosed herein. | 2015-05-14 |
20150132241 | ANTIPERSPIRANT ACTIVE COMPOSITIONS HAVING SEC CHROMATOGRAM EXHIBITING HIGH SEC PEAK 4 INTENSITY - An aluminum salt composition comprising (a) an aluminum salt having an aluminum to chloride molar ratio of about 0.3:1 to about 3:1, an OH:Al molar ratio of about 2:1 to about 2.6:1, exhibiting a Size Exclusion Chromatography (SEC) chromatogram having a SEC Peak 4 to Peak 3 intensity ratio of at least 7, and a Peak 4 intensity greater than a Peak 5 intensity in aqueous solution, and (b) at least one buffer chosen from an amino acid, glycine, and betaine, wherein a molar ratio of buffer to aluminum is about 0.1:1 to about 3:1. | 2015-05-14 |
20150132242 | Method of Making an Aluminum Salt Composition - A method of making aluminum salt compositions using a combination of a basic organic buffer with a source of alkaline earth metal ions. This selection of basic organic buffer provides for a lower alkaline earth metal salt content in the composition made by the method. | 2015-05-14 |
20150132243 | METHOD FOR THE APPLICATION OF A PIGMENT DYEING COMPOSITION BASED ON SPECIFIC ACRYLIC POLYMER AND ON SILICONE COPOLYMER, AND APPROPRIATE DEVICE - A subject-matter of the present invention is a method for dyeing human keratinous fibres, which consists in applying a dyeing composition using a container comprising a removable applicator comprising a permeable material through which the composition can pass, the composition being applied by bringing the applicator into contact with the dry or wet fibres, the said composition comprising at least one aqueous dispersion of particles of hybrid hydrophobic film-forming acrylic polymer, at least one linear block silicone copolymer and at least one pigment. The method according to the invention makes it possible to obtain a coloured coating which is persistent towards shampooing operations or washing operations and which leaves the treated fibres individualized, with an improved cosmetic feel; the treated fibres being the hair (roots, sidelocks); non-head hair (beard, moustache); eyelashes or eyebrows. | 2015-05-14 |
20150132244 | AGENT AND METHOD FOR THE TEMPORARY DEFORMATION OF KERATIN FIBRES - Powdered cosmetic compositions containing a) 5 wt % to 20 wt % hydrophobized metal oxide powder, b) 40 wt % to 94 wt % organic polyol, c) 0.1 wt % to 15 wt % emulsifier agent, d) 0 to 40 wt % water are particularly suitable for reshaping keratinic fibers, and impart shine, texture, and smoothness. | 2015-05-14 |
20150132245 | METHOD FOR DETOXIFICATION OR MEASUREMENT OF AT LEAST ONE COMPOUND OR AT LEAST ONE FLUID IN A HOST BODY - The present invention comprises a method for detoxification or measurement of the concentration of at least one compound in a host body, wherein said host body comprises a sorption material of at least one phase over a certain period of time, where sorption of said at least one compound in at least one phase of said sorption material is effected and the content of the at least one compound in said sorption material is optionally analysed. Use of a sorption material for providing an estimate of the concentration of compounds present in a host body, use of a sorption material for detoxification and sorption material for diagnostic use is also comprised in the present application. | 2015-05-14 |
20150132246 | MAKE-UP COSMETIC COMPOSITION CONTAINING MQ SILICONE RESIN AND PROPYL SILSESQUIOXANE RESIN - The present invention relates to a make-up cosmetic composition containing MQ silicone resin and propyl silsesquioxane resin, and, more specifically, relates to a make-up cosmetic composition which contains MQ silicone resin and propyl silsesquioxane resin, gives an outstanding moisturising impression and is free from any pulling phenomenon. | 2015-05-14 |
20150132247 | COSMETIC CARE COMPOSITION AND METHOD USING AN ELASTIC MIXTURE - The present invention relates to a method of cosmetic care that consists of applying, on at least one area of the body, a cosmetic composition containing an elastic mixture consisting of at least one starch, at least one polymer selected from polyvinyl alcohols, vinylpyrrolidone polymers and copolymers and latex, at least one polyol, and optionally water. | 2015-05-14 |
20150132248 | ANTIMICROBIAL POLYURETHANE MATERIALS AND METHODS OF FORMING AND USING SAME - Antimicrobial quaternized polyurethane materials and methods of forming and using the materials are disclosed. The quaternized polyurethane antimicrobial materials may be synthesized from one or more diisocyanates and one or more diols or triols. The quaternized polyurethane materials may be stand alone or coated onto other surfaces, such as medical devices, table tops, air/water filters, or the like to provided desired antimicrobial devices and surfaces. | 2015-05-14 |
20150132249 | STIMULI RESPONSIVE POLYESTER AMIDE PARTICLES - A composition including a solution suitable for introduction into a blood vessel comprising particles including a treatment agent and a tunable stimuli-responsive polymer. A method including introducing a delivery device into a blood vessel; and introducing a solution into the blood vessel, the solution including particles comprising a treatment agent and a tunable stimuli-responsive polymer. A method including combining a treatment agent and a tunable stimuli-responsive polymer; and forming particles of the combination suitable for delivery through a blood vessel. | 2015-05-14 |
20150132250 | EXTRACORPOREAL DEVICES AND METHODS OF TREATING COMPLICATIONS OF PREGNANCY - The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. | 2015-05-14 |
20150132251 | Biodegradable Elastomeric Patch for Treating Cardiac or Cardiovascular Conditions - Provided herein is a biodegradable elastomeric patch that can be implanted on a heart or other portions of the cardiovascular system to repair tissue deficiencies or tissue damage. The biodegradable elastomeric patch may be engineered to have mechanical properties similar to that of soft tissue and to provide mechanical support to the damaged tissue. The biodegradable elastomeric patch also may comprise therapeutic agents to aid in the healing process. Methods also are provided for using a biodegradable elastomeric patch for treating patients suffering from tissue damage or tissue deficiencies in the cardiac or cardiovascular system. | 2015-05-14 |
20150132252 | Composition and Method for Attraction of Emerald Ash Borer Agrilus Planipennis Fairmaire (Coleoptera: Buprestidae) - The invention disclosed relates to a novel composition and use thereof, for the attraction and detection of emerald ash borer, | 2015-05-14 |
20150132253 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER - The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof. | 2015-05-14 |
20150132254 | SYNERGISTIC TUMOR TREATMENT WITH EXTENDED-PK IL-2 AND THERAPEUTIC AGENTS - The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer. | 2015-05-14 |
20150132255 | HIV VACCINE - The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides. | 2015-05-14 |
20150132256 | DETECTING AND MONITORING MUTATIONS IN HISTIOCYTOSIS - Provided is methods of detecting a mutation in a histiocytosis patient. Also provided is methods of selecting and/or applying treatment or therapy for a histiocytosis patient. Further provided is a method of treating a patient having a histiocytosis. | 2015-05-14 |
20150132257 | FUSION MOLECULES AND IL-15 VARIANTS - The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention. | 2015-05-14 |
20150132258 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS - Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | 2015-05-14 |
20150132259 | Polyalkylene Polymer Compounds and Uses Thereof - The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C. | 2015-05-14 |
20150132260 | Anellovirus Genome Quantification as a Biomarker of Immune Suppression - The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment. | 2015-05-14 |
20150132261 | TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON - An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN. | 2015-05-14 |
20150132262 | Mutant Adeno-Associated Virus Virions and Methods of Use Thereof - The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof. | 2015-05-14 |
20150132263 | COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES - The present disclosure relates to engineered bacteriophage vector compositions comprising nucleic acids that express recombinant nucleases. Also provided are methods of using engineered bacteriophage vectors to effect genomic disruption or targeted gene disruption in prokaryotes. The disclosed compositions and methods are useful for reducing antibiotic resistance in bacteria cells. | 2015-05-14 |
20150132264 | BACTERIUM FOR USE AS A PROBIOTIC FOR NUTRITIONAL AND MEDICAL APPLICATIONS - A first aspect of the invention relates to the bacterial species | 2015-05-14 |
20150132265 | Methods and Compositions for Treating Disease - The present invention relates to methods and compositions for treating a subject comprising destroying diseased cells in the subject. The methods comprise obtaining a population of cells from a subject and determining the activity of at least one disease marker gene within the population of the obtained cells. A polynucleotide molecule that encodes a polypeptide that is lethal to the cells is then introduced into the cells, where the expression of the lethal polypeptide is controlled by the promoter of at least one of the disease marker genes previously identified. After introduction of the polynucleotide, the cells are treated with conditions to induce expression of the lethal polypeptide to destroy the cells that are expressing the disease marker gene(s). After destruction of the diseased cells, the remaining live cells, which did not express the lethal polypeptide to an extent necessary to kill the cells, are separated from the dead cells, and the live cells are restored to the subject. | 2015-05-14 |
20150132266 | NON-EXPANDED POST-NATAL MULTILINEAGE-INDUCIBLE CELLS - A method of isolating non-expanded post-natal multilineage-inducible cells has the steps of obtaining a biological sample from an animal; isolating bone marrow from the biological sample, isolating total nuclear cells (TNCs) obtained from the bone marrow, incubating the total nuclear cells in the presence of an antibody or a cell adhesion substrate, separating the cells to isolate non-expanded post-natal multilineage-inducible cells and isolating the non-expanded post-natal multilineage-inducible cells in the absence of expansion. | 2015-05-14 |
20150132267 | FIBROBLAST MIXTURES AND METHODS OF MAKING AND USING THE SAME - The present disclosure provides a non-autologous product that is a mixture of two or more cells or tissue cultures of fibroblast, or extracts from cultures, or media cultures, isolated from separate individuals, either homogeneous or heterogeneous. The cells or factors are blended together in a product that imparts desired characteristics to the skin of a recipient who is not a source of the mixture. The present disclosure also relates to methods of making and using and/or culturing the fibroblasts including to optimize the potency of the mixture to impart one or more the desired characteristics to the skin of a recipient. | 2015-05-14 |
20150132269 | NUCLEASE-MEDIATED REGULATION OF GENE EXPRESSION - The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell. | 2015-05-14 |
20150132270 | STRAINS OF LACTOBACILLUS WITH ANTIFUNGAL PROPERTIES - The present invention relates to novel strains of | 2015-05-14 |
20150132271 | READY TO EAT COLD BEVERAGE CAKES WITH INGREDIENTS - Cold and ready to eat beverage cakes, and with a variety of ingredient combinations are suitable for healthy consumption. The beverage cakes are soft in texture and high in nutrition. People can save the time and energy of preparing and cooking of the food. Serving size can be a single serving, and a six pack of servings. Beverage cakes are also created as beverage egg cakes, beverage plus salt source cakes, beverage seafood cakes, beverage meat cakes, beverage bubbles, beverage balls, beverage patties, and beverage sausages. They can be served as cold and hot food for breakfast, lunch, snack, and dinner. They can also be used as animal food, baby food, for children with less teeth, for elderly people, and for sick people. Cold and ready to eat beverage cakes with ingredients offer the consumers an easy and convenient way to obtain an affordable, nutritious, and delicious meal. | 2015-05-14 |
20150132272 | COMPOSITIONS AND METHODS FOR DIMINISHING AN IMMUNE RESPONSE - The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purity and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders. | 2015-05-14 |
20150132273 | Nutritional Compositions and Methods for Treating Cognitive Impairment - A nutritional supplement that contains folinic acid, folic acid, USP, methylfolic acid, cobalamin, magnesium, docosahexaenoic acid, phosphatidylcholine-docosahexaenoic acid, phosphatidylethanolamine-docosahexaenoic acid. | 2015-05-14 |
20150132274 | Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients - A method of reducing or treating parainfluenza or influenza virus infection in an immunocompromised patient by administering to the respiratory tract of the patient a composition comprising a therapeutically effective amount of protein having sialidase activity. | 2015-05-14 |
20150132275 | COMPOSITION FOR PREVENTING HEADACHES - The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches. | 2015-05-14 |
20150132276 | CARTILAGE REGENERATION-PROMOTING AGENT - It is an object of the present invention to provide a chondrogenesis promoter that is safe and exhibits a chondrogenesis-promoting effect by daily ingestion. It is also an object of the invention to provide a proteoglycan synthesis promoter that exhibits a proteoglycan synthesis-promoting effect by ingestion. Provided are a chondrogenesis promoter and a proteoglycan synthesis promoter each containing a milk-derived basic protein fraction as an active ingredient. Synthesis of proteoglycan and formation of a cartilage can be promoted by oral ingestion of the milk-derived basic protein fraction. A hydrolysate of the milk-derived basic protein fraction also has a similar chondrogenesis-promoting effect. | 2015-05-14 |
20150132277 | Monomeric Forms of Human Aminoacyl-tRNA Synthetases Having Non-Canonical Biological Activities - Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. | 2015-05-14 |
20150132278 | METHODS OF TREATMENT WITH ARGININE DEIMINASE - The present invention relates generally to methods of treating cancer with arginine deiminase, and in particular pegylated arginine deiminase. | 2015-05-14 |
20150132279 | RADIATION STERILIZATION-RESISTANT PROTEIN COMPOSITION - A protein composition which comprises a mixture of glycine, phenylalanine and histidine and/or a cellulose ether derivative as an additive and has resistance to radiation sterilization. | 2015-05-14 |
20150132280 | THEACRINE-BASED SUPPLEMENT AND METHOD OF USE THEREOF - A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. | 2015-05-14 |
20150132281 | VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE - A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R | 2015-05-14 |
20150132282 | TREATMENT OF SOCIAL ANXIETY DISORDER, OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER USING BOTULINUM TOXIN - Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be | 2015-05-14 |
20150132283 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin. | 2015-05-14 |
20150132284 | METHOD OF TREATING ULCERATIVE COLITIS - Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. | 2015-05-14 |
20150132285 | Proteinase-engineered Cancer Vaccine Induces Immune Responses to Prevent Cancer and to Systemically Kill Cancer Cells - The present invention provides a method of making a proteinase-engineered cancer vaccine for treating a cancer patient, especially for cancer patient at advanced/metastatic stage. The cancer vaccine comprises dead cancer cells with unbroken plasma membrane wherein the extracellular proteins and extracellular portion of membrane proteins are cleaved by proteinase digestion. The cancer vaccine may be derived from cancer cell lines or patients' cancer cells. The present invention provides a method of treating a cancer patient by administrating an effective amount of the cancer vaccine to the patient. In a clinical trial with 35 cancer patients, the cancer vaccine therapy brings cancer-free lives (no detectable tumor, micro tumor or cancer cells after treatment) back to 40% of these patients. The cancer vaccine therapy for the first time brings the promise of cure to this deadly disease. The present invention further provides a method of obtaining cancer-specific immune components from blood of individuals treated with the cancer vaccine. | 2015-05-14 |
20150132286 | PANCREATIC CANCER TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas. | 2015-05-14 |
20150132287 | METHODS OF DECREASING LEPTIN LEVELS OR ACTIVITY FOR TREATING INFLAMMATION - The present invention is directed to methods for modulating the Th/Th2 cell balance toward anti-inflammatory cytokine producing cells in a subject comprising decreasing the amount, the expression, or the activity of leptin in a subject sufficient to modulate the Th1/Th2 cell balance toward anti-inflammatory cytokine producing cells. The invention is also directed to methods of treatment of an immune-related disorder in a subject comprising decreasing the amount, the expression, or the activity of leptin in the subject sufficient to treat the immune-related disorder. | 2015-05-14 |
20150132288 | ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF - The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment. | 2015-05-14 |
20150132289 | METHODS AND COMPOSITIONS FOR TREATING PSC (PRIMARY SCLEROSING CHOLANGITIS) OR PBC (PRIMARY BILIARY CIRRHOSIS) WITH ANTI-CD3 IMMUNE MOLECULE THERAPY - A method or composition comprising an anti-CD3 immune molecule for treatment of PSC (primary sclerosing cholangitis) or PBC (primary biliary cirrhosis) in a subject. | 2015-05-14 |
20150132290 | Methods and Compositions for Infusion of Transiently Engrafting, Selected Populations of Allogeneic Lymphocytes to Treat Cancer - The invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host. | 2015-05-14 |
20150132291 | METHODS FOR TREATMENT OF GASTRIC CANCER - The application provides methods of detection, diagnosis, prognosis, prophylaxis and treatment of folate receptor-alpha-expressing gastric cancer using antibodies that specifically bind to folate receptor alpha. | 2015-05-14 |
20150132292 | USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERS - Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor. | 2015-05-14 |
20150132293 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME - The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides. | 2015-05-14 |
20150132294 | COMPOSITIONS AND METHODS FOR CHARACTERIZING, REGULATING, DIAGNOSING, AND TREATING CANCER - The present invention relates to compositions and methods for characterizing, regulating, diagnosing, and treating cancer. For example, the present invention provides compositions and methods for inhibiting tumorigenesis of certain classes of cancer cells, including breast cancer cells and preventing metastasis. The present invention also provides systems and methods for identifying compounds that regulate tumorigenesis. | 2015-05-14 |
20150132295 | METHODS AND COMPOSITIONS FOR DIAGNOSING, PROGNOSING, AND TREATING ENDOMETRIOSIS - This document provides methods and materials related to genetic variations associated with endometriosis. For example, this document provides methods for using such genetic variations to assess risk of, or susceptibility of developing or diagnosing endometriosis. | 2015-05-14 |
20150132296 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS - Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed. | 2015-05-14 |
20150132297 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients. | 2015-05-14 |
20150132298 | GEMCITABINE PRODRUGS AND USES THEREOF - The present invention provides compounds according to formula I: | 2015-05-14 |
20150132299 | METHODS OF TREATING NEURONAL INFLAMMATION USING AN IL-31 MONOCLONAL ANTIBODY - Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 2015-05-14 |
20150132300 | METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN SPINAL CORD CELLS USING AN IL-31RA OR OSMR-B ANTAGONIST - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 2015-05-14 |
20150132301 | Combination Therapy for Treatment of Cancer - The present invention provides methods comprising combination therapy for treating cancer. In particular, the present invention provides Wnt pathway inhibitors in combination with MAPK pathway inhibitors for the treatment of cancer and other diseases. In some embodiments, the MAPK pathway signaling activation is due to a mutation in a MAPK pathway component. In some embodiments, the MAPK pathway signaling component is Ras, Raf, MEK, or ERK. | 2015-05-14 |
20150132302 | Vaccine and uses thereof - The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, e.g., to suppress or prevent an immune response and/or to treat or prevent an autoimmune disease. | 2015-05-14 |
20150132303 | ANTI ONCOSTATIN M RECEPTOR BETA ANTIBODY - A monoclonal antibody against oncostatin M specific receptor beta subunit, a hybridoma capable of producing the same and a medicament for treating atopic dermatitis comprising the same. | 2015-05-14 |
20150132304 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75 - NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. | 2015-05-14 |
20150132305 | Humanized Antibodies Targeting the EC1 Domain of Cadherin-11 and Related Compositions and Methods - The present invention relates to humanized antibodies that specifically bind an EC1 domain of a mammalian Cadherin-11 protein and compositions (e.g., pharmaceutical compositions) comprising such antibodies. The invention also relates to methods for treating Cadherin-11-mediated disorders in a mammalian subject by administering a therapeutically effective amount of a humanized antibody of the invention. Cadherin-11-mediated disorders suitable for treatment by the methods of the invention include inflammatory disorders (e.g., inflammatory joint disorders, such as rheumatoid arthritis), fibrosis and cancer. | 2015-05-14 |
20150132306 | HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES - We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These are promising therapeutic agents. | 2015-05-14 |
20150132307 | BISPECIFIC ANTIBODIES AGAINST HUMAN TWEAK AND HUMAN 1L17 AND USES THEREOF - The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof | 2015-05-14 |
20150132308 | Combination Therapy Using Anti-EGFR And Anti-HER2 Antibodies - The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer. | 2015-05-14 |
20150132309 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 2015-05-14 |
20150132310 | METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS - The present invention relates to methods of treating and preventing | 2015-05-14 |
20150132311 | TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF - The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions. | 2015-05-14 |
20150132312 | SYSTEMS AND METHODS FOR EXTRACORPOREAL BLOOD MODIFICATION - The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject. Previous techniques for removal of biological materials from blood, such as hemodialysis and plasmapheresis, were generally non-specific (i.e., they removed a multitude of proteins/toxins from the blood). By contrast, novel methods and devices described herein are capable of removing specific or single substances such as proteins from biological fluids such as blood in a specific manner. Such highly specific protein removal has a broad array of clinical applications, including treatment of inflammatory conditions and autoimmune diseases. | 2015-05-14 |
20150132313 | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS - The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders. | 2015-05-14 |
20150132314 | ANTI-IL-17F ANTIBODIES AND METHODS OF USE THEREOF - This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2015-05-14 |
20150132315 | METHODS TO IMPAIR HEMATOLOGIC CANCER PROGENITOR CELLS AND COMPOUNDS RELATED THERETO - Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3Rα or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieties such as, for example, radioisotopes or chemotherapeutics. | 2015-05-14 |
20150132316 | MONOCLONAL ANTIBODIES AGAINST NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 2015-05-14 |
20150132317 | METHODS AND COMPOSITIONS FOR TREATING NEUROBLASTOMA - Methods and compositions for treating neuroblastoma are disclosed. | 2015-05-14 |
20150132318 | SOLUBLE VEGFR-1 VARIANTS FOR DIAGNOSIS OF PREECLAMPSIA - Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same. | 2015-05-14 |
20150132319 | TGF-BETA1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF - Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein. | 2015-05-14 |
20150132320 | MUTATED ANTI-TNFa ANTIBODIES AND METHODS OF THEIR USE - The present invention is directed to modified antibodies, including anti-TNFα antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies. | 2015-05-14 |
20150132321 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 - The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via β1 integrin activation. | 2015-05-14 |
20150132322 | METHOD OF GENERATING HUMAN MONOCLONAL ANTIBODIES - This invention provides a human antibody, a hybridoma cell line for the production of the antibody, a reconstituted mouse strain for the production of the hybridoma, and methods of producing and using thereof. | 2015-05-14 |
20150132323 | Anti-FOLR1 Immunoconjugate Dosing Regimens - Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects. | 2015-05-14 |
20150132324 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE - Tubulysin compounds of the formula (I) | 2015-05-14 |
20150132325 | NOVEL COMPOSITIONS AND USES THEREFOR - The invention is directed to the use of (i) a first antigen corresponding to a target antigen of interest, together with (ii) a second antigen, corresponding to a modified form of the target antigen, whose rate of intracellular proteolytic degradation is increased, enhanced or otherwise elevated relative to the first antigen, in compositions and methods for inducing both humoral and cellular immunity in an individual. The ability to provide compositions, which are capable of inducing both host-protective antibody and cell-mediated immune responses, facilitates the generation of immunogenic compositions capable of combating, inter alia, conditions that have long latency periods and, therefore, benefit from the dual approach of prophylaxis and therapy in one delivery. | 2015-05-14 |
20150132326 | IMMUNOSUPPRESSIVE BLOOD CELLS AND METHODS OF PRODUCING THE SAME - The present invention refers to a method of producing immunosuppressive blood cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease. | 2015-05-14 |